Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples